von Willebrand factor/ADAMTS13 axis and venous thromboembolism in moderate-to-severe COVID-19 patients

Br J Haematol. 2021 Mar;192(6):1097-1100. doi: 10.1111/bjh.17216. Epub 2020 Dec 24.

Maxime Delrue^{1

2}, Virginie Siguret^{1

3}, Marie Neuwirth^{1

3}, Bérangère Joly^{1

2}, Nicolas Beranger^{1

2}, Damien Sène⁴, Benjamin G Chousterman^{5

6}, Sebastian Voicu^{7

8}, Philippe Bonnin^{9

10

11}, Bruno Mégarbane^{7

8}, Alain Stépanian^{1

2}

¹ Department of Hematology, Lariboisière Hospital, Paris University, Paris, France.
² EA 3518, Paris University, Paris, France.
³ INSERM, UMRS 1140, Paris University, Paris, France.
⁴ Department of Internal Medicine, Lariboisière Hospital, Paris University, Paris, France.
⁵ Department of Anesthesiology and Critical Care, Lariboisière Hospital, Paris University, Paris, France.
⁶ INSERM, UMRS 942, Université de Paris, Paris, France.
⁷ Department of Medical and Toxicological Critical Care, Lariboisière Hospital, Paris University, Paris, France.
⁸ INSERM, UMRS 1144, Paris University, Paris, France.
⁹ Department of Clinical Physiology, Lariboisière Hospital, Paris University, Paris, France.
¹⁰ INSERM U1265, INSERM, Université de Paris, Paris, France.
¹¹ INSERM U1148-Laboratory for Vascular and Translational Science, Université de Paris, Paris, France.

No abstract available

Keywords: ADAMTS13; COVID-19; venous thrombosis; von Willebrand factor.

Publication types